Format

Send to

Choose Destination
Cancer Cell Int. 2019 Jan 3;19:2. doi: 10.1186/s12935-018-0720-y. eCollection 2019.

T cell receptor-engineered T cells for leukemia immunotherapy.

Zhang Y1,2, Li Y1,2.

Author information

1
1Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, 601 Huang Pu Da Dao Xi, Guangzhou, 510632 People's Republic of China.
2
2Department of Hematology, First Affiliated Hospital, Jinan University, Guangzhou, 510632 China.

Abstract

At present, refractory and relapse are major issues for leukemia therapy and a major cause of allogeneic hematopoietic stem cell transplant failure. Over the last decade, many studies have demonstrated that adoptive cancer antigen-specific T cell therapy is an effective option for leukemia therapy. Recently, T cell immunotherapy studies have mainly focused on chimeric antigen receptor- and T cell receptor-engineered T cells. Clinical trials involving chimeric antigen receptor-engineered T cells have been a major breakthrough and became a novel therapy for leukemia. As another potential therapy for leukemia, clinical application of TCR-engineered T cells remains in its infancy. This article presents a review of the current status of anti-leukemia immunotherapy using leukemia antigen-specific TCR-engineered T cells.

KEYWORDS:

Immunotherapy; Leukemia; T cell receptor-engineered T cells

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center